Moderna Inc. (MRNA) saw its stock price surge 5.17% during intraday trading on Friday, following a series of positive analyst actions.
The rally was driven by multiple investment firms raising their price targets for the biotechnology company. Piper Sandler increased its target price to $77 from $69, while Jefferies raised its target to $53 from $45, though maintaining a hold rating on the stock.
Analysts have been actively weighing in on Moderna and other healthcare stocks this week, with mixed opinions emerging about the sector's prospects. The upward revisions in price targets appear to have boosted investor confidence in the company's outlook.